Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

AMAM | Ambrx Biopharma Inc ADR

Index	-	P/E	-	EPS (ttm)	-2.02	Insider Own	4.01%	Shs Outstand	61.75M	Perf Week	4.10%
Market Cap	690.37M	Forward P/E	-	EPS next Y	-0.20	Insider Trans	402.47%	Shs Float	59.27M	Perf Month	-20.82%
Income	-78.00M	PEG	-	EPS next Q	-0.05	Inst Own	78.68%	Short Float / Ratio	1.76% / 2.69	Perf Quarter	-30.82%
Sales	7.40M	P/S	93.29	EPS this Y	36.21%	Inst Trans	-1.30%	Short Interest	1.04M	Perf Half Y	25.34%
Book/sh	4.05	P/B	2.76	EPS next Y	-6.31%	ROA	-39.56%	Target Price	23.38	Perf Year	916.36%
Cash/sh	3.82	P/C	2.93	EPS next 5Y	21.70%	ROE	-50.68%	52W Range	0.38 - 16.86	Perf YTD	392.51%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-30.05%	52W High	-33.69%	Beta	-2.36
Dividend %	-	Quick Ratio	13.28	Sales past 5Y	-4.53%	Gross Margin	38.76%	52W Low	2842.11%	ATR	0.89
Employees	66	Current Ratio	13.28	Sales Q/Q	-	Oper. Margin	-901.66%	RSI (14)	43.49	Volatility	5.60% 8.92%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-	Profit Margin	-1053.72%	Rel Volume	0.00	Prev Close	11.18
Shortable	Yes	LT Debt/Eq	0.04	Earnings	-	Payout	-	Avg Volume	387.80K	Price	11.18
Recom	1.33	SMA20	-2.02%	SMA50	-15.06%	SMA200	12.72%	Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-25-23	Initiated	JMP Securities	Mkt Outperform	$15
Sep-12-23	Initiated	BTIG Research	Buy	$26
Jul-31-23	Initiated	RBC Capital Mkts	Outperform	$29
Jun-14-23	Initiated	B. Riley Securities	Buy	$26
Jun-02-23	Initiated	Oppenheimer	Outperform	$30
May-19-23	Initiated	Cantor Fitzgerald	Overweight	$25
Apr-07-22	Initiated	Robert W. Baird	Outperform	$16
Feb-28-22	Initiated	Goldman	Neutral	$6
Jul-13-21	Initiated	Goldman	Buy	$53
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	BofA Securities	Buy	$26

Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-26-23 08:30AM	Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023 (GlobeNewswire)
Sep-18-23 08:00AM	Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +10.22%
Sep-05-23 08:30AM	Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences (GlobeNewswire)
Aug-11-23 09:20AM	RBC Predicts 100% Gains for These 2 Stocks Heres Why They Have Strong Upside (TipRanks)
08:30AM	Loading…
Aug-01-23 08:30AM	Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs (GlobeNewswire)
Jul-31-23 09:51AM	Adobe upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Jul-28-23 08:30AM	Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023 (GlobeNewswire)
Jul-19-23 09:03AM	FDA Grants Fast Track Designation for Ambrxs ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
Jul-02-23 05:05AM	TipRanks Perfect 10 List: These 2 Top-Rated Stocks Tick All the Boxes (TipRanks)
Jun-28-23 08:30AM	Ambrx Announces Closing of $75 Million Market Priced Registered Offering (GlobeNewswire)
Jun-05-23 08:30AM	Ambrx Appoints Jared Kelly as General Counsel (GlobeNewswire) -11.06%
May-30-23 09:01AM	Ambrx to Present at Multiple Upcoming Investor Meetings (GlobeNewswire) +5.71%
May-24-23 08:30AM	Ambrx Announces $75 Million Market Priced Registered Offering (GlobeNewswire) +5.20%
May-18-23 04:05PM	Ambrx Appoints Stephen Glover as Chairman of its Board of Directors (GlobeNewswire)
04:23PM	Loading…
May-11-23 04:23PM	Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences (GlobeNewswire)
May-04-23 04:05PM	Ambrx Expands Leadership Team with Appointment of Andrew Aromando as Chief Operating Officer (GlobeNewswire)
Apr-19-23 09:00AM	Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-01-23 09:14AM	Ambrx Biopharma Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-27-23 08:30AM	Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-13-23 08:00AM	Ambrx Raises $78 Million and Completes its ATM Program (Business Wire) +5.78%
Mar-07-23 03:32PM	Why Shares of Ambrx Biopharma Fell Tuesday (Motley Fool) -26.00%
Mar-06-23 09:00AM	Ambrx to Commence Trading on Nasdaq (Business Wire) +95.02%
Mar-01-23 08:00AM	ACE-Breast-02 Pivotal Phase 3 Study of Ambrxs ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results (Business Wire) -8.40%
Feb-17-23 06:45AM	Ambrx Biopharma Inc. (NYSE:AMAM) hedge funds owners may be pleased with recent gains after 35% loss over the past year (Simply Wall St.) +16.91%
Feb-16-23 10:50AM	Why Ambrx Biopharma Shares Are Surging Today? (Benzinga) +53.59%
08:00AM	ARX517, Ambrxs Proprietary Anti-PSMA ADC, Shows Encouraging Single-Agent Safety and Efficacy Data in Patients with Advanced Prostate Cancer (Business Wire)
Feb-13-23 08:00AM	Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer (Business Wire)
Feb-03-23 08:00AM	Ambrx Biopharma Strengthens Clinical Leadership with Appointment of Sandra Aung, Ph.D. as Head of Clinical Development (Business Wire)
Jan-16-23 05:05AM	The past year for Ambrx Biopharma (NYSE:AMAM) investors has not been profitable (Simply Wall St.)
05:31PM	Loading…
Dec-16-22 05:31PM	Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price (Business Wire) +5.33%
Dec-11-22 12:37PM	Meet the Biotech Stock That Jumped Over 1000% in One Day (TipRanks)
Dec-09-22 09:04AM	Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate (Benzinga) +1,007.59%
08:00AM	Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment (Business Wire)
Dec-06-22 09:35AM	Can Ambrx Biopharma (NYSE:AMAM) Afford To Invest In Growth? (Simply Wall St.)
Nov-29-22 08:30AM	Interim Data from Ambrxs Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.25%
Nov-09-22 08:00AM	Ambrx Announces NovoCodexs Dosing of First Patient with ARX305, Ambrxs Investigational Antibody Drug Conjugate Targeting CD70 (Business Wire)
Nov-01-22 04:05PM	Ambrx Biopharma Inc. Appoints Daniel OConnor as Chief Executive Officer (Business Wire) -7.37%
Oct-19-22 07:13AM	Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason (Benzinga) -14.39%
Oct-18-22 04:05PM	Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update (GlobeNewswire)
Oct-11-22 04:05PM	Ambrx Biopharma to Host Corporate Update Conference Call (GlobeNewswire)
Aug-29-22 04:05PM	Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update (Business Wire)
Aug-17-22 11:20AM	Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review (Benzinga) -10.16%
Aug-16-22 04:05PM	Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian (Business Wire)
Jul-05-22 04:05PM	Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors (Business Wire)
Jun-28-22 04:05PM	Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference (Business Wire)
Jun-20-22 08:20AM	Investors are selling off Ambrx Biopharma (NYSE:AMAM), lack of profits no doubt contribute to shareholders one-year loss (Simply Wall St.)
Jun-06-22 08:00AM	Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors (Business Wire)
May-27-22 04:05PM	Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences (Business Wire)
May-17-22 04:05PM	Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer (Business Wire)
May-06-22 04:05PM	Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences (Business Wire)
07:18AM	What Kind Of Shareholders Own Ambrx Biopharma Inc. (NYSE:AMAM)? (Simply Wall St.)
May-02-22 04:05PM	Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F (Business Wire)
Apr-26-22 11:01PM	Ambrx Biopharma Inc. (AMAM) Q4 2021 Earnings Call Transcript (Motley Fool)
04:05PM	Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update (Business Wire)
Apr-25-22 04:05PM	Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer (Business Wire)
Apr-21-22 04:05PM	Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022 (Business Wire)
Apr-14-22 09:55AM	Ambrx Biopharma Inc. Sponsored ADR (AMAM) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-08-22 08:00AM	Ambrx Biopharma Inc. to Present at Oppenheimers 32nd Annual Healthcare Conference (Business Wire)
Feb-28-22 04:05PM	Ambrx Biopharma Inc. to Participate in the Cowen 42nd Annual Health Care Conference (Business Wire)
Feb-15-22 08:00AM	Ambrx Biopharma Inc. Announces Submission of IND Application for ARX305 with the U.S. FDA (Business Wire)
Feb-07-22 08:00AM	Ambrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee (Business Wire) +6.14%
Dec-29-21 05:37AM	Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Dec-09-21 12:30PM	Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial (Benzinga) +11.54%
09:00AM	Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium (Business Wire)
Nov-19-21 04:05PM	Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium (Business Wire) -6.42%
Nov-08-21 04:15AM	What Type Of Shareholders Make Up Ambrx Biopharma Inc.'s (NYSE:AMAM) Share Registry? (Simply Wall St.)
Nov-04-21 08:00AM	Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer (Business Wire)
Nov-01-21 04:05PM	Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference (Business Wire)
Oct-28-21 04:05PM	Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update (Business Wire)
Oct-04-21 08:00AM	Ambrx Announces Positive Data on ARX788 for the Treatment of HER2+ Gastric Cancer Presented at CSCO (Business Wire)
Sep-09-21 04:30PM	Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-03-21 08:00AM	Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors (Business Wire)
Jul-18-21 11:39AM	Goldman Sachs: These 3 Stocks Could Spike Over 60% (TipRanks)
Jun-30-21 08:00AM	Ambrx Appoints Sonja Nelson as Chief Financial Officer (Business Wire) +7.93%
Jun-17-21 11:15PM	Ambrx Announces Pricing of Initial Public Offering (Business Wire)

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	10% Owner	Sep 18	Buy	9.24	751,233	6,944,924	69,465,823	Sep 19 04:49 PM
Cormorant Asset Management, LP	10% Owner	Sep 15	Buy	9.05	1,401,505	12,680,677	68,714,590	Sep 19 04:49 PM
Cormorant Asset Management, LP	10% Owner	Apr 20	Buy	11.60	886,634	10,285,220	67,313,085	Apr 20 06:04 PM
Cormorant Asset Management, LP	10% Owner	Apr 19	Buy	11.15	951,909	10,612,357	66,426,451	Apr 20 06:04 PM
Cormorant Asset Management, LP	10% Owner	Apr 18	Buy	11.27	3,376,646	38,053,112	65,474,542	Apr 20 06:04 PM
Cormorant Asset Management, LP	10% Owner	Apr 17	Buy	10.67	562,121	5,999,461	62,097,896	Apr 17 05:46 PM
Cormorant Asset Management, LP	10% Owner	Apr 14	Buy	9.96	841,967	8,384,307	61,535,775	Apr 17 05:46 PM
Cormorant Asset Management, LP	10% Owner	Apr 13	Buy	9.16	1,193,808	10,935,520	60,693,808	Apr 17 05:46 PM
Cormorant Asset Management, LP	10% Owner	Mar 16	Buy	10.15	500,000	5,074,250	53,500,000	Mar 16 06:04 PM
Cormorant Asset Management, LP	10% Owner	Mar 15	Buy	10.60	250,000	2,648,875	53,000,000	Mar 16 06:04 PM
Cormorant Asset Management, LP	10% Owner	Mar 14	Buy	9.95	250,000	2,488,275	52,750,000	Mar 16 06:04 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMAM | Ambrx Biopharma Inc ADR

Upgrade your FINVIZ experience